This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
vaccines: Archive
Should You Buy Cadence Design Systems (CDNS) After Golden Cross?
by Zacks Equity Research
Is it a good or bad thing when a stock experiences a golden cross technical event?
CDNSNegative Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Novavax (NVAX) Q2 Earnings Miss, Cuts '22 Sales Guidance by Half
by Zacks Equity Research
Novavax (NVAX) reports dismal results in second-quarter 2022. The stock dives in after-market trading after management slashes revenue guidance for 2022 by half.
PFENegative Net Change MRNANegative Net Change NVAXNegative Net Change BNTXNegative Net Change
medical vaccines
Neuronetics (STIM) Just Flashed Golden Cross Signal: Do You Buy?
by Zacks Equity Research
When a stock experiences a golden cross technical event, good things could be on the horizon. How should investors react?
STIMPositive Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
BJ's Wholesale Club (BJ) Just Flashed Golden Cross Signal: Do You Buy?
by Zacks Equity Research
When a stock experiences a golden cross technical event, good things could be on the horizon. How should investors react?
BJPositive Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Moderna (MRNA) Beats on Q2 Earnings, Starts $3B Buyback Program
by Zacks Equity Research
Moderna's (MRNA) earnings and sales beat expectations. The company also announces another $3-billion buyback program. Stock gains in pre-market.
AZNPositive Net Change LLYPositive Net Change MRNANegative Net Change JAZZPositive Net Change
biotechs medical messenger-rna vaccines
NBT Bancorp (NBTB)'s Technical Outlook is Bright After Key Golden Cross
by Zacks Equity Research
When a stock experiences a golden cross technical event, good things could be on the horizon. How should investors react?
NBTBPositive Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Moderna (MRNA) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
Investor focus is likely to be on the progress of Moderna's (MRNA) late-stage pipeline candidates on the second-quarter earnings call that can lower its dependence on Spikevax.
AZNPositive Net Change MRNANegative Net Change ADCTPositive Net Change IONSPositive Net Change
biotechs medical messenger-rna vaccines
Clearway Energy (CWEN)'s Technical Outlook is Bright After Key Golden Cross
by Zacks Equity Research
Should investors be excited or worried when a stock's 50 -day simple moving average crosses above the 200-day simple moving average?
CWENNegative Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Bavarian Nordic (BVNRY)'s Technical Outlook is Bright After Key Golden Cross
by Zacks Equity Research
Is it a good or bad thing when a stock experiences a golden cross technical event?
BVNRYPositive Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Sanofi (SNY) Q2 Earnings & Sales Beat, Ups 2022 Growth View
by Zacks Equity Research
Sanofi (SNY) beats second-quarter estimates for earnings and sales. Dupixent drives sales growth and a strong recovery in travel vaccines. The company raises its earnings growth guidance for 2022.
REGNPositive Net Change SNYPositive Net Change LLYPositive Net Change NVAXNegative Net Change
medical pharmaceuticals vaccines
Novavax (NVAX) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
On Novavax's (NVAX) second-quarter earnings call, investors' focus is likely to be on the sales figures of its COVID-19 vaccine.
AZNPositive Net Change BAYRYPositive Net Change NVAXNegative Net Change IONSPositive Net Change
biotechs vaccines
Valmont Industries (VMI) Now Trades Above Golden Cross: Time to Buy?
by Zacks Equity Research
Is it a good or bad thing when a stock experiences a golden cross technical event?
VMIPositive Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Greif (GEF) Now Trades Above Golden Cross: Time to Buy?
by Zacks Equity Research
When a stock experiences a golden cross technical event, good things could be on the horizon. How should investors react?
GEFNegative Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Pfizer Q2 Preview: Quarterly Estimates Display Robust Growth
by Derek Lewis
The Zacks - Medical Sector has held up relatively well year-to-date, decreasing approximately 12% in value vs. the S&P 500's decline of 15%.
PFENegative Net Change
earnings medical pharmaceuticals vaccines
After Golden Cross, Covenant Logistics (CVLG)'s Technical Outlook is Bright
by Zacks Equity Research
When a stock experiences a golden cross technical event, good things could be on the horizon. How should investors react?
CVLGPositive Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Novavax (NVAX) Up as CDC Endorses COVID Jab for Use in Adults
by Zacks Equity Research
Following the endorsement by the U.S. CDC, Novavax (NVAX) can now start immunizations with its COVID-19 vaccine as a primary two-dose regimen for use in adults in the United States.
PFENegative Net Change MRNANegative Net Change NVAXNegative Net Change BNTXNegative Net Change
biotechs medical vaccines
Pfizer (PFE), BioNTech Seek EU Nod for Omicron-Based COVID Jab
by Zacks Equity Research
Pfizer (PFE) and BioNTech (BNTX) complete a regulatory filing for their Omicron-specific bivalent COVID-19 vaccine in the EU. The bivalent vaccine has been developed to target the Omicron BA.1 subvariant.
PFENegative Net Change MRKNegative Net Change MRNANegative Net Change BNTXNegative Net Change
biotechs medical messenger-rna pharmaceuticals vaccines
Enphase Energy (ENPH) Now Trades Above Golden Cross: Time to Buy?
by Zacks Equity Research
Is it a good or bad thing when a stock experiences a golden cross technical event?
ENPHNegative Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
After Golden Cross, Bassett Furniture (BSET)'s Technical Outlook is Bright
by Zacks Equity Research
Good things could be on the horizon when a stock experiences a golden cross event. How should investors react?
BSETNegative Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Novavax (NVAX) Down as EU Adds Side Effects to COVID Jab Label
by Zacks Equity Research
The administration of Novavax's (NVAX) COVID-19 vaccine leads to some cases of severe allergic reactions as well as skin problems, per a safety update issued by the EMA.
PFENegative Net Change MRNANegative Net Change NVAXNegative Net Change BNTXNegative Net Change
biotechs medical vaccines
Novavax's (NVAX) Protein-Based COVID Jab Gets EUA in the US
by Zacks Equity Research
Following the grant of emergency use authorization by the FDA, Novavax's (NVAX) COVID-19 vaccine is the first protein-based COVID vaccine authorized for use in the United States.
PFENegative Net Change MRNANegative Net Change NVAXNegative Net Change BNTXNegative Net Change
biotechs medical vaccines
This Medical Supplier Is Pushing All-Time Highs
by Derek Lewis
McKesson shares have been scorching-hot year-to-date, increasing by more than 30% in value and extensively outperforming both its Zacks Sector and the S&P 500.
MCKPositive Net Change AMNNegative Net Change
medical vaccines
Moderna (MRNA) Starts Early-Stage Nipah Virus Vaccine Study
by Zacks Equity Research
Moderna (MRNA) doses the first participant in the phase I study of its investigational mRNA vaccine, targeting the Nipah virus. It also starts a mid-stage study evaluating its Zika virus vaccine.
MRKNegative Net Change MRNANegative Net Change SPPIPositive Net Change JAZZPositive Net Change
biotechs medical messenger-rna vaccines
Seattle Genetics (SGEN) Now Trades Above Golden Cross: Time to Buy?
by Zacks Equity Research
Should investors be excited or worried when a stock's 50 -day simple moving average crosses above the 200-day simple moving average?
SGENPositive Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Novavax (NVAX) Inks COVID Jab Supply Deal With US Government
by Zacks Equity Research
Novavax (NVAX) inks a deal with the US government to supply 3.2 million doses of COVID shot. But the deal will be effective only if the vaccine gets EUA from the FDA. It also needs CDC recommendation.
PFENegative Net Change MRNANegative Net Change NVAXNegative Net Change BNTXNegative Net Change
biotechs medical vaccines